Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

If you feel as if people’s faces are getting smoother and firmer every day, you’re not imagining it. Neuromodulator ...

While research shows estrogen cream may help improve skin dryness, texture and elasticity in menopausal women, experts say it ...

Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release capsules) for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. In ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Analysis of paired biopsies showed increased tumor infiltration of CD25+ activated CD8+ T cells and NK cells post-MDNA11 treatment. Combination Dose ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...